Bio-Thera Solutions Ltd - Asset Resilience Ratio

Latest as of December 2024: 4.09%

Bio-Thera Solutions Ltd (688177) has an Asset Resilience Ratio of 4.09% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 688177 strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥90.22 Million
≈ $13.20 Million USD Cash + Short-term Investments

Total Assets

CN¥2.21 Billion
≈ $322.74 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2020–2024)

This chart shows how Bio-Thera Solutions Ltd's Asset Resilience Ratio has changed over time. See 688177 equity financing ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Bio-Thera Solutions Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Bio-Thera Solutions Ltd worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥90.22 Million 4.09%
Total Liquid Assets CN¥90.22 Million 4.09%

Asset Resilience Insights

  • Limited Liquidity: Bio-Thera Solutions Ltd maintains only 4.09% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Bio-Thera Solutions Ltd Industry Peers by Asset Resilience Ratio

Compare Bio-Thera Solutions Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 10.93%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
Biotechnology 2.30%
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
Biotechnology 6.52%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%

Annual Asset Resilience Ratio for Bio-Thera Solutions Ltd (2020–2024)

The table below shows the annual Asset Resilience Ratio data for Bio-Thera Solutions Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 4.09% CN¥90.22 Million
≈ $13.20 Million
CN¥2.21 Billion
≈ $322.74 Million
-10.38pp
2023-12-31 14.47% CN¥331.03 Million
≈ $48.44 Million
CN¥2.29 Billion
≈ $334.67 Million
-14.42pp
2022-12-31 28.90% CN¥629.89 Million
≈ $92.17 Million
CN¥2.18 Billion
≈ $318.96 Million
+5.87pp
2021-12-31 23.03% CN¥602.83 Million
≈ $88.21 Million
CN¥2.62 Billion
≈ $383.06 Million
-16.91pp
2020-12-31 39.94% CN¥955.77 Million
≈ $139.86 Million
CN¥2.39 Billion
≈ $350.19 Million
--
pp = percentage points

About Bio-Thera Solutions Ltd

SHG:688177 China Biotechnology
Market Cap
$1.03 Billion
CN¥7.06 Billion CNY
Market Cap Rank
#8927 Global
#2249 in China
Share Price
CN¥17.06
Change (1 day)
+4.22%
52-Week Range
CN¥16.37 - CN¥34.72
All Time High
CN¥71.90
About

Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. It offers QLETLI for the treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, and uveitis; POBEVCY to treat patients with metast… Read more